{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:12Z","timestamp":1787169732037,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Fedratinib, an oral Janus kinase\u20102 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts \u226550\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/l, based on outcomes from the phase 3, placebo\u2010controlled JAKARTA trial in JAK\u2010inhibitor\u2010na\u00efve MF, and the phase 2, single\u2010arm JAKARTA2 trial in patients previously treated with ruxolitinib. We evaluated the efficacy and safety of fedratinib 400\u2009mg\/day in patients with baseline platelet counts 50 to &lt;100\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/l (\u201cLow\u2010Platelets\u201d cohorts), including 14\/96 patients (15%) in JAKARTA and 33\/97 (34%) in JAKARTA2. At 24\u2009weeks, spleen response rates were not significantly different between the Low\u2010Platelets cohort and patients with baseline platelet counts \u2265100\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/l (\u201cHigh\u2010Platelets\u201d cohort), in JAKARTA (36% vs. 49%, respectively;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u20090.37) or JAKARTA2 (36% vs. 28%;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u20090.41). Symptom response rates were also not statistically different between the Low\u2010 and High\u2010Platelets cohorts. Fedratinib was generally well\u2010tolerated in both platelet\u2010count cohorts. New or worsening thrombocytopaenia was more frequent in the Low\u2010Platelets (44%) versus the High\u2010Platelets (9%) cohort, but no serious thrombocytopaenia events occurred. Thrombocytopaenia was typically managed with dose modifications; only 3\/48 Low\u2010Platelets patients discontinued fedratinib due to thrombocytopaenia. These data indicate that fedratinib 400\u2009mg\/day is safe and effective in patients with MF and low pretreatment platelet counts, and no initial fedratinib dose adjustment is required for these patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.18207","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T08:45:32Z","timestamp":1651049132000},"page":"317-327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase\u20102 (\n                    <scp>JAK2<\/scp>\n                    ), in patients with myelofibrosis and low pretreatment platelet counts"],"prefix":"10.1111","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology Guy's and St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre Nijmegen  Nijmegen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms AOU Careggi, University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques, INSERM, CIC1427 AP\u2010HP, H\u00f4pital Saint\u2010Louis, Universit\u00e9 de Paris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Insubria  Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam UMC, Vrije Universiteit Amsterdam  Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelonitda","family":"Rose","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Sy","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center at UT Health San Antonio MD Anderson  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0736"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.347"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23505"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01373.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.827413"},{"key":"e_1_2_9_11_1","first-page":"89","article-title":"Myelofibrosis\u2010associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal TI","year":"2014","journal-title":"Int J Gen Med"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.12.001"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.07.008"},{"key":"e_1_2_9_14_1","unstructured":"Jakafi\u00ae (ruxolitinib) prescribing information. Incyte Corporation Wilmington DE. Rev 01\/2020. [cited 2021 Mar 19]. Available from:https:\/\/www.jakafi.com\/pdf\/prescribing\u2010information.pdf"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16462"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0642-0"},{"key":"e_1_2_9_21_1","unstructured":"Inrebic\u00ae (fedratinib) prescribing information. Celgene Corporation Summit NJ; Rev 08\/2019. [cited 2022 Feb 15]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212327s000lbl.pdf"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17727"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:59:02Z","timestamp":1692817142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/bjh.18207"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18207","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}